共 50 条
- [41] COMBINING PD-1/PD-L1 BLOCKADE AND RANKL INHIBITORS TO TREAT BREAST CANCERS UNRESPONSIVE TO STANDARD THERAPYJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A50 - A51Pilard, C.Roncarati, P.Hendrick, E.Lebeau, A.Bruyere, D.Lerho, T.Ancion, M.Reynders, C.Delvenne, P.Herfs, M.Hubert, P.
- [42] Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy EfficacyFRONTIERS IN IMMUNOLOGY, 2020, 11Zuazo, MirenArasanz, HugoBocanegra, AnaFernandez, GonzaloChocarro, LuisaVera, RuthKochan, GrazynaEscors, David
- [43] Circulating Exhausted PD-1+CD39+ Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis BlockadeCANCERS, 2022, 14 (15)Martinez-Gomez, CarlosMichelas, MarieScarlata, Clara-MariaSalvioni, AnnaGomez-Roca, CarlosSarradin, VictorLauzeral-Vizcaino, FrancoiseFeliu, VirginieDupret-Bories, AgnesFerron, GwenaelSarini, JeromeDevaud, ChristelDelord, Jean-PierreBalanca, Camille-CharlotteMartinez, AlejandraAyyoub, Maha
- [44] OnxoVEXmGM-CSF promotes systemic response to PD-L1 /PD-1 blockade in multiple mouse syngeneic tumor modelsCANCER RESEARCH, 2020, 80 (16)Cooke, KeeganEstrada, JuanMitchell, PetiaZhan, JinghiuBeltran, Pedro J.Qing, JingCanon, Jude
- [45] Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasisBIOMATERIALS, 2021, 275Chen, ChuanrongGuo, QianqianFu, HaoYu, JianWang, LitingSun, YingZhang, JialiDuan, Yourong
- [46] CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 BlockadeCANCER DISCOVERY, 2018, 8 (09) : 1156 - 1175Chen, LimoDiao, LixiaYang, YongbinYi, XiaohuiRodriguez, LeticiaLi, YanliVillalobos, Pamela A.Cascone, TinaLiu, XiTan, LinLorenzi, Philip L.Huang, AnfeiZhao, QiangPeng, DiFradette, Jared J.Peng, David H.Ungewiss, ChristinRoybal, JonathonTong, PanOba, JunnaSkoulidis, FerdinandosPeng, WeiyiCarter, Brett W.Gay, Carl M.Fan, YouhongClass, Caleb A.Zhu, JingfenRodriguez-Canales, JaimeKawakami, MasanoriByers, Lauren AverettWoodman, Scott E.Papadimitrakopoulou, Vassiliki A.Dmitrovsky, EthanWang, JingUllrich, Stephen E.Wistuba, Ignacio I.Heymach, John V.Qin, F. Xiao-FengGibbons, Don L.
- [47] TIGIT+CD8+T cells limit the efficacy of PD-L1 blockade plus chemoradiotherapy in MSS locally advanced rectal cancer via NECTIN2-TIGIT interplayANNALS OF ONCOLOGY, 2024, 35 : S219 - S219Zhu, Z.Tang, W.Lv, Y.Xu, Y.Zhou, P.Ye, L.Xu, J.
- [48] Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockadeCANCER RESEARCH, 2023, 83 (07)Patil, Namrata S.Srivats, ShyamChoi, YoonhaGuan, XiangnanNabet, BarzinMcGinnis, LisaChiang, EugeneDunkle, AlexisO'Gorman, BillChang, Patrick S.Hu, RuozhenSilva, JohnHan, JoyAu-Yeung, AmeliaTakahashi, ChikaraMolden, NandiniDaggumati, PallaviConnolly, WendyJohnson, MelissaAbreu, Delvys RodriguezCho, Byoung ChulItaliano, AntoineGil-Bazo, IgnacioFelip, EnriquetaMellman, IraMeng, RaymondMariathasan, SanjeevJohnston, RobertShames, David S.
- [49] ANTI-TIGIT ANTIBODY TIRAGOLUMAB LEVERAGES MYELOID CELLS AND REGULATORY T CELLS TO IMPROVE PD-L1 CHECKPOINT BLOCKADEJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A495 - A495Patil, NamrataMeng, RaymondJohnston, RobertChang, PatrickSrivats, ShyamChoi, YoonhaGuan, XiangnanNabet, BarzinMcGinnis, LisaChiang, EugenePham, ThinhDunkle, AlexisO'Gorman, BillMellman, IraHu, RuozhenSilva, JohnHan, JoyAu-Yeung, AmeliaTakahashi, ChikaraMolden, NandiniDaggumati, PallaviConnolly, WendyJohnson, MelissaRodriguez Abreu, DelvysCho, Byoung ChulItaliano, AntoineGil Bazo, IgnacioFelip, EnriquetaMariathasan, SanjeevBais, CarlosShames, David
- [50] CD155 Cooperates with PD-1/PD-L1 to Promote Proliferation of Esophageal Squamous Cancer Cells via PI3K/Akt and MAPK Signaling PathwaysCANCERS, 2022, 14 (22)Tang, XiyangYang, JieShi, AnpingXiong, YanluWen, MiaomiaoLuo, ZhonglinTian, HuanhuanZheng, KaifuLiu, YujianShu, ChenMa, NanWang, RuiZhao, Jinbo